29th Apr 2015 09:28
LONDON (Alliance News) - Ergomed PLC on Wednesday said its co-development partner Aeterna Zentaris Inc has received a positive recommendation from Canada's Data Safety Monitoring Board for a study on the ZoptEC product.
ZoptEC is involved in a phase 3 clinical study on using zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer.
The Data Safety Monitoring Board has recommended the trial continue as planned.
"We are very pleased with this positive recommendation from the DSMB for the Phase 3 ZoptEC study. The study is progressing well - patient recruitment ahead of schedule with approximately 90% of patients enrolled. We believe that zoptarelin doxorubicin has the potential to provide a much needed new treatment option to women with late-stage endometrial cancer, and look forward to progressing this study with Aeterna Zentaris," said Ergomed Chief Executive Miroslav Reljanovic.
Shares in Ergomed were up 1.6% to 169.20 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L